#StopTheWait – Tour n’ Cure Egypt | Clapboard Ad Archive

73

#StopTheWait - Tour n’ Cure | Clapboard Ad Archive

Tour n’ Cure’s #StopTheWait campaign, launched in 2017 by BBDO, confronts the global Hepatitis C epidemic with a bold creative construct that reframes patient waiting as the central injustice of inaccessible treatment, anchoring the narrative in the arresting contrast between Lionel Messi’s energetic, event-filled two years and Melanie’s agonizingly static wait for a cure. Positioned at the intersection of health advocacy and celebrity power, the film leverages Messi’s universal profile and the emotionally charged symbolism of time’s passage to galvanize both public sentiment and industry attention toward eradicating a disease that holds 100 million lives in stasis. Eschewing literal depictions of suffering, the work exemplifies what Clapboard’s taxonomy would classify as FORMAT#3—Symbolize the Problem, distilling the issue into a potent analogy that transcends medical jargon or policy debate and instead presents the human cost of lost years and thwarted aspirations. By juxtaposing a global football star’s kinetic ascent with the flatline narrative of a patient denied agency and hope, the campaign not only elevates urgency but also contextualizes healthcare disparity for an international audience, driving home the need for immediate change. This approach is sharply calibrated for impact in Egypt—a market where Hepatitis C prevalence makes the message locally resonant—while the involvement of Messi casts the issue into the broader sphere of sports, popular culture, and social responsibility, broadening the advocacy coalition. With over 5.5 million views, the film’s reach underlines its effectiveness as a vehicle for mass awareness and issue-priming, demonstrating the capacity of emotive storytelling and symbolic frameworks to transform a medical crisis into an actionable global movement. The campaign’s creative strategy underscores Tour n’ Cure’s positioning as a brand dedicated to affordable, accessible care and models how brands in healthcare can shape public conversations by fusing purpose with visibility. The campaign earns 73/100 in Clapboard’s global creative archive. As rising public anxiety around health equity reframes industry priorities, #StopTheWait signals how cultural symbolism and movement-building can accelerate change in markets where technical innovation is not enough.

Credits

Client

Tour n’ Cure

Agency

BBDO

President

Hussam Moro

Executive Creative Director

Ahmed El Keiy

Creative Director

Mohamed Fathy

Art Director

Kamel Basha

Copywriter

Ahmed Hany

Strategic Planner

Noor Hassanein, Hend Ghorab

Account Management

Dalia AbdelShafi, Dalia Khairy

Head Of Social Media

Rula El Kaliouby

Category Mind Map

48%

The #StopTheWait campaign by Tour n’ Cure seeks to challenge the prolonged delay faced by over 100 million Hepatitis C patients awaiting access to life-saving and prohibitively expensive treatments. The brand proposition centers on urgency and hope, positioning itself as a catalyst for change to eradicate the disease and make cures more accessible and affordable. By drawing a stark contrast between the rapid progression of Lionel Messi’s career over two years and the stagnant, uncertain wait endured by a patient named Melanie, the campaign underscores the human cost of delayed treatment, emphasizing the need to accelerate access and end this wait. Strategically, the campaign leverages a compelling narrative that juxtaposes a globally recognized figure with an everyday patient to generate emotional resonance and broaden appeal. Targeting both the general public and healthcare stakeholders, the campaign taps into universal values of fairness and the right to timely medical intervention. Featuring Lionel Messi amplifies reach and credibility, aligning the message with perseverance and progress while personalizing the issue through Melanie’s story. This dual storytelling approach is designed to mobilize awareness, advocacy, and pressure on healthcare systems to prioritize Hepatitis C treatment availability. The campaign’s film medium and emotional storyline deliver a cinematic yet relatable experience, aiming to transform passive viewers into active participants in a global health movement. The choice to publish in Egypt, a country heavily impacted by Hepatitis C, further ensures local relevance while inviting international attention. Overall, the campaign strategically blends star power, personal narrative, and healthcare urgency to spotlight an overlooked issue and inspire systemic change.

FORMAT#3 SYMBOLIZE THE PROBLEM — Uses symbols or analogies to represent the problem instead of showing it literally. This campaign hinges on a symbolic juxtaposition: Messi’s fast-paced, eventful life versus Melanie’s prolonged waiting for a Hepatitis C cure. Rather than just depicting the medical issue directly, it creates a conceptual analogy between time enjoyed by a global football star and the stagnant existence of a patient denied affordable treatment. The campaign’s core message—#StopTheWait—is powerfully conveyed through this metaphorical comparison, emphasizing the emotional weight of waiting as the true problem to be eradicated.

1. Gilead Sciences – Market Positioning Gilead Sciences leads the Hepatitis C treatment market globally by offering highly effective direct-acting antiviral (DAA) therapies like Sovaldi and Harvoni. Their strategy focuses on innovation, improving cure rates with shorter treatment durations, and expanding access through pricing programs and partnerships, positioning them as a pioneering and patient-centric pharmaceutical leader. 2. AbbVie – Market Positioning AbbVie differentiates itself by providing robust Hepatitis C treatment options like Viekira Pak and Mavyret, emphasizing comprehensive care solutions with a focus on affordability and accessibility. Their positioning integrates advanced research with real-world patient support programs, aiming to simplify treatment regimens and broaden global disease eradication efforts. 3. Merck & Co. – Market Positioning Merck positions itself as a key player in the Hepatitis C space by developing innovative, effective antiviral treatments backed by strong clinical research. Their approach emphasizes reliability, safety, and broad-spectrum efficacy, supported by collaborations that target underserved markets to enhance global disease management and patient outreach. 4. Roche – Market Positioning Roche leverages its diagnostic expertise combined with pharmaceutical solutions to address Hepatitis C comprehensively. Their market stance highlights integrated testing and treatment protocols, aiming to improve patient outcomes through precise diagnostics and personalized medicine, reinforcing their role as a holistic healthcare partner. 5. Bristol-Myers Squibb – Market Positioning Bristol-Myers Squibb focuses on delivering next-generation Hepatitis C antivirals like Daklinza, emphasizing innovation in treatment options that cater to diverse patient needs, including difficult-to-treat populations. Their strategy stresses commitment to research, expanding global access, and collaborating with healthcare systems to ensure effective disease management and cure.

Q: What is #StopTheWait about? A: #StopTheWait is a 2017 healthcare campaign from Tour n’ Cure, created by BBDO and launched in Egypt, aiming to eradicate Hepatitis C by spotlighting the prolonged wait faced by over 100 million patients for affordable treatment. The campaign’s central creative idea is a film featuring football icon Lionel Messi, contrasting his dynamic two-year journey with the stagnant life of a patient named Melanie, who is forced to wait for a cure. By leveraging Messi’s global profile and a powerful narrative, the campaign seeks to raise awareness, mobilize advocacy, and drive systemic change in access to Hepatitis C treatment. Q: What creative device does #StopTheWait use? A: #StopTheWait employs FORMAT#3 SYMBOLIZE THE PROBLEM, as classified by Clapboard’s creative taxonomy. Rather than depicting the medical issue literally, the campaign uses a symbolic juxtaposition: Messi’s fast-paced, eventful life is contrasted with Melanie’s prolonged, stagnant wait for a Hepatitis C cure. This analogy powerfully conveys the emotional and psychological toll of waiting, making the problem relatable and urgent. By representing the issue through metaphor, the campaign elevates the narrative beyond statistics, focusing on the human experience at the heart of the healthcare crisis. Q: What is the campaign proposition for #StopTheWait? A: The campaign proposition for #StopTheWait centers on urgency and hope, positioning Tour n’ Cure as a catalyst for change in the fight against Hepatitis C. The brand challenges the prolonged delays and prohibitive costs that prevent over 100 million patients from accessing life-saving treatments. By contrasting Messi’s rapid career progression with Melanie’s stagnant wait, the campaign underscores the human cost of inaction and appeals to both the general public and healthcare stakeholders. The message emphasizes fairness, the right to timely medical intervention, and the need to accelerate access to cures in a market where barriers remain high. Q: How does #StopTheWait rank in Clapboard's archive? A: In Clapboard's global ad archive, #StopTheWait holds a Clapboard Campaign Score of 73/100. This score reflects the campaign’s creative ambition, execution quality, and cultural relevance as assessed by Clapboard’s curatorial standards. Q: Who are the competitors in Tour n’ Cure's category? A: In the Hepatitis C treatment and healthcare market, Tour n’ Cure faces competition from several major pharmaceutical brands. Gilead Sciences leads with innovative direct-acting antivirals and a focus on expanding access through partnerships. AbbVie emphasizes comprehensive, affordable care with advanced research and patient support. Merck & Co. is recognized for reliable, effective antivirals and outreach to underserved markets. Roche combines diagnostic expertise with integrated treatment protocols for personalized care. Bristol-Myers Squibb delivers next-generation antivirals, prioritizing innovation and global access for diverse patient populations.